Key result
Ranolazine treatment significantly improved quality of life scores in 80.6% of patients with microvascular angina (P<0.01) and reduced healthcare interactions from 93.5% to 35.5% (P<0.01).
Why the study?
Does ranolazine improve angina scores and quality of life in patients with severe refractory angina due to microvascular angina?
Cohort (n=31)
Does ranolazine improve angina scores and quality of life in patients with severe refractory angina due to microvascular angina?
p-value: p=<0.01
Ranolazine significantly improves symptom control, quality of life, and reduces healthcare interactions in patients with severe refractory microvascular angina.
No takes yet. Share an insight, caveat, or question.
May support ranolazine for microvascular angina symptoms; hypothesis-generating and requires RCTs before practice change.
Rayner‐Hartley et al. (2018) conducted a cohort in Severe refractory angina due to microvascular angina (n=31). Ranolazine vs. Baseline (pre-treatment) was evaluated on Improvement in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form scores (p=<0.01). Ranolazine treatment significantly improved quality of life scores in 80.6% of patients with microvascular angina (P<0.01) and reduced healthcare interactions from 93.5% to 35.5% (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: